New blood test claims to detect 50‑plus cancers before symptoms – but there’s no evidence it can reduce your risk of dying from cancer
Cancer isn’t the leading cause of death in the United States; heart disease ranks first in that regard. But it’s cancer that strikes fear into the hearts of many Americans.
Cancer can take an excruciating toll on its millions of victims and their family members. Cancer treatments are often highly toxic, and the disease is increasingly striking people at younger ages, which is why it accounts for more years of potential life lost than heart disease.
So when a blood test comes along that claims to be able to screen for over 50 cancers at once in a single blood draw before symptoms appear – as is the case for the Galleri test, by the biotech company GRAIL – it might seem like society has a Holy Grail of modern medicine at their fingertips.
But a closer look at the evidence suggests that the Galleri test is not yet the universal screening breakthrough patients and doctors hope for.
As a physician who studies early cancer detection, and as chair of the American Cancer Society’s screening guideline development group, I have been following this test’s development with interest.
While the Galleri test certainly shows great promise, clinical trial data indicates that it struggles with early-stage cancer detection and has not yet been shown to lower the risk of death from cancer or prevent advanced cancer. Across all cancer stages, the test missed over two-thirds of cancer cases.
On Sept. 23, 2026, an advisory panel to the U.S. Food and Drug Administration voted to recommend approval of the Galleri test. While a recommendation from the FDA’s advisory panel is not the same as full approval from the agency, it marks a critical first step in the process of potentially making the test widely available to the American public. The FDA has not yet announced when it will make a decision on the test.
But even as the advisory panel approved the test, panelists recommended that the word “early” be removed from “early cancer detection test” in product labeling. Panel members were not convinced the test can find cancers at their earliest and most curable stages, and they expressed uncertainty about the test’s benefit to patients at this time.
Given this uncertainty, careful scrutiny of the data behind the test can help doctors and patients make informed decisions about whether to use it.
What is the Galleri test? How does it work?
Galleri is part of an emerging class of multicancer early detection tests. These tests do not diagnose cancer: If a test is positive, further evaluation is necessary to determine whether cancer is present, and, if so, what type of cancer. It is offered as a screening test, similar to mammography for breast cancer screening or PSA testing for prostate cancer screening, but with the........
